NEWS
Interra Health is profitable, growing at approximately 40% annually and projected to exceed $100 million in revenue in 2026, executives said.
Healthcare technology companies DoseSpot and Arrive Health have merged to combine an electronic prescribing platform with medical and pharmacy benefits data to advance real-time medication price transparency for providers and patients.
The new company, called Interra Health, combines Arrive Health’s coverage and pricing network with DoseSpot’s e-prescribing capabilities to support prescribing decisions and help patients access the right medication at the lowest cost, according to the companies.
Bain Capital Tech Opportunities is backing the deal and will serve as majority owner. PSG, the former majority owner of DoseSpot, will be a minority owner. Additional minority investors include Providence and UPMC Enterprises.
The combined company is profitable, growing at approximately 40% annually and projected to exceed $100 million in revenue in 2026, executives said.
Josh Weiner, former CEO of DoseSpot, will serve as CEO and a board member of the newly combined company, while Kyle Kiser, former CEO of Arrive Health, will serve as a board member and senior advisor.
Arrive Health brings a network providing real-time coverage and affordability insights from payers and pharmacies to the point of care, while DoseSpot offers prescribing and engagement tools that integrate directly into electronic health records and digital health and telehealth platforms. Fifty million prescriptions are sent via DoseSpot each year, according to the company.
With the combined technologies, Interra Health unifies coverage, prescribing, price transparency and access insights to support faster and better-informed treatment decisions, improving medication access and adherence and lowering administrative burden, executives said. Interra Health serves 800,000 providers, and the company’s infrastructure is purpose-built to serve artificial-intelligence-native healthcare companies, executives noted.
DoseSpot and Arrive Health have partnered for several years, and both companies were in the process of raising funds in 2025, Weiner told Fierce Healthcare in an exclusive interview about the merger.
“We saw an opportunity to create a broad platform for prescribing access and affordability. Bain Capital was the partner that really came forward with that thesis and vision that Kyle and I agreed with completely, and it was really apparent to us that one plus one was going to equal three,” Weiner said. “Arrive Health had built a network of nearly 700,000 providers. DoseSpot came serving 100,000 prescribers, and the opportunity to marry the breadth of the Arrive network with the depth of the DoseSpot solutions was just an opportunity that we are really excited about.”
Arrive Health provides real-time medical and pharmacy benefit information and integrates with EHR and e-prescribing vendors. “The goal is to drive the most affordable, most accessible decision as that decision is being made so that downstream of that, we prevent administrative waste, we prevent prescription abandonment and we prevent all of the confusion and complexity that often exists in today’s prescription value chain,” Kiser said.
He added, “We also provide electronic prior authorization connectivity, where we can leverage EMR connections and our connectivity to the payer and pharmacy benefit manager community to resolve prior auths as those decisions are being made in the EMR or by care teams. Beyond that, we’ve started to expand capabilities more broadly with care teams, so, as patients seek access to meds—and that’s sometimes with pharmacies, sometimes that’s with other care team members—we’re also providing data solutions to help speed and enable that process.”
The combined capabilities of DoseSpot and Arrive Health address existing friction points in the prescribing experience. Providers and patients typically don’t know what a medication will actually cost or whether it will be covered until after the prescription leaves the exam room. Coverage restrictions, prior authorization requirements and higher out-of-pocket costs surface only after a prescription is sent. That disconnect contributes to prior authorization delays, prescription abandonment and billions in avoidable friction.
Interra Health’s integrated offering helps providers access real-time coverage, cost and access insights at the point of care while patients see clear coverage, affordability and availability information. PBMs and payers can access benefit information in the workflow, optimizing prescribing decisions and improving member experience. Pharma companies can connect patients to therapy more efficiently by aligning coverage, affordability and support earlier in the care journey, executives said.
With the integration, the two companies’ capabilities are now bidirectional, Weiner noted.
“Arrive Health brings real-time price transparency on every prescription event. We can deepen that experience into the prescribing workflow that DoseSpot is delivering, and then the other way around is that Arrive’s network is across the broad networks in Epic, Oracle and athena, the broad EMR and PBM networks. We can bring capabilities that DoseSpot has been working on into that environment that give patients empowerment and choice in terms of how they can see and handle each of their prescriptions,” he said. “We are bringing true price transparency that allows a patient to see what they’re going to pay at the pharmacy right when they’re being prescribed the med, and then allows them to evaluate options right there with their provider.”
Interra Health’s data show that approximately one-third of patients who view pharmacy options choose to transfer their prescriptions after reviewing available options.
The merger comes as there is renewed focus on drug pricing transparency and PBM reform and as patients face rising medication costs.
“In this world where consumers and families are feeling so much pressure from the inflation that’s taken place in recent years, there hasn’t been a bigger focus ever on medication affordability and price transparency around that, and that’s driving so many partnership conversations and opportunities forward,” Weiner said.
Within the health insurance industry, there is an ongoing shift toward greater patient responsibility for prescription drug costs, but patients need better decision-making tools, Kiser noted.
“What the future needs to look like to better serve patients is consumer choice at the point of care and throughout the patient experience and so that requires some meaningful change in how prescription decisions are made and how we communicate with patients during that process,” he said. “Wen you lead a network business, you’re often very dependent on lots of other partners to set the pace on innovation. What gets me most excited is that now with this combination, when you combine the Arrive network and the DoseSpot set of solutions to really set our own pace for that type of change, that the pace of innovation is now within our control, and we can be better prepared to meet the need of patients as the market is changing.”
Backed by Bain Capital, the company plans to make major investments in innovation. “Everything that we do in the next few quarters and putting our organizations together is identifying which of the friction points in the prescribing journey that we are uniquely suited to reduce and then get after it with all of our technology partners,” Weiner said.
“We are proud to have been selected as the partner of choice by DoseSpot and Arrive Health. The combined business is uniquely positioned to address the most significant pain points in the prescription journey for patients, prescribers, pharmacies and pharma companies,” said Michael Grandfield, partner at Bain Capital Tech Opportunities, in a statement.
“We look forward to leveraging our business-building capabilities and deep sector expertise to support Interra Health’s future growth,” said Todd Markson, partner at Bain Capital Tech Opportunities.
Read the article at https://www.fiercehealthcare.com/health-tech/dosespot-and-arrive-health-merge-build-prescription-drug-access-and-affordability.